Adamis Pharmaceuticals Corp (NASDAQ:ADMP) – Equities research analysts at B. Riley issued their FY2022 EPS estimates for Adamis Pharmaceuticals in a research note issued to investors on Wednesday, March 14th, according to Zacks Investment Research. B. Riley analyst A. D’silva anticipates that the specialty pharmaceutical company will post earnings per share of ($0.20) for the year. B. Riley has a “Buy” rating and a $7.50 price target on the stock.
Other research analysts have also issued reports about the stock. Maxim Group set a $5.00 target price on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 19th. Raymond James Financial set a $7.00 price objective on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 23rd. Finally, Zacks Investment Research upgraded shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $6.50.
NASDAQ:ADMP opened at $3.45 on Thursday. The stock has a market capitalization of $113.52, a price-to-earnings ratio of -3.83 and a beta of 0.32. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.24 and a current ratio of 2.44. Adamis Pharmaceuticals has a 12-month low of $2.35 and a 12-month high of $6.45.
Several hedge funds have recently made changes to their positions in ADMP. Wells Fargo & Company MN purchased a new position in shares of Adamis Pharmaceuticals during the 2nd quarter worth about $169,000. Northern Trust Corp lifted its holdings in shares of Adamis Pharmaceuticals by 5.5% during the 2nd quarter. Northern Trust Corp now owns 51,108 shares of the specialty pharmaceutical company’s stock worth $266,000 after acquiring an additional 2,686 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Adamis Pharmaceuticals by 22.2% during the 2nd quarter. Vanguard Group Inc. now owns 942,940 shares of the specialty pharmaceutical company’s stock worth $4,903,000 after acquiring an additional 171,167 shares during the period. Advisor Group Inc. lifted its holdings in shares of Adamis Pharmaceuticals by 149.9% during the 3rd quarter. Advisor Group Inc. now owns 56,001 shares of the specialty pharmaceutical company’s stock worth $292,000 after acquiring an additional 33,591 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Adamis Pharmaceuticals by 131.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock worth $143,000 after acquiring an additional 15,577 shares during the period. Institutional investors and hedge funds own 12.42% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “B. Riley Weighs in on Adamis Pharmaceuticals Corp’s FY2022 Earnings (NASDAQ:ADMP)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/research-analysts-issue-forecasts-for-adamis-pharmaceuticals-corps-fy2022-earnings-admp.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.